Several possible studies
Story checked
Nearly one third of patients with advanced melanoma saw tumors disappear completely after receiving TIL therapy plus pembrolizumab immunotherapy (opens in a new tab)
news-medical.net · 2026-10-24
Short answer
Several possible studiesStudy not confirmed.
Several potential source studies were identified, but no single match could be confirmed. The article's claims remain unverified.
These papers were considered as possible sources, but none could be confirmed as the study behind this story.
Share this check
The story
Nearly one third of patients with advanced melanoma saw tumors disappear completely after receiving TIL therapy plus pembrolizumab immunotherapy
news-medical.net · 2026-10-24
The story’s checkable claims.
Read the original story (opens in a new tab)NewsLink checks it
Multiple potential source studies identified.
Several studies match details in the article, but none could be confirmed as its source. The claims have not been assessed against a source study.
View article claimsSearch result
Several studies could fit.
Several studies match details in the article, but none could be confirmed as its source. The claims have not been assessed against a source study.
Evidence layer
Claim by claim
The article's claims are listed below. Without a confirmed source study, they have not been assessed as supported or unsupported.
Reading mode
Scan verdicts. Open evidence only when needed.
Claim 1 of 6Not checkedNearly one third (29.2 percent) of patients with advanced melanoma saw their tumors disappear completely on scans after receiving lifileucel TIL therapy alongside pembrolizumab as a first-line treatment.View evidenceHide evidence
As stated29.2 percent
Not checked
No source study was confirmed for this article. This claim remains unverified, rather than assessed as supported or unsupported.
Claim 2 of 6Not checkedApproximately two thirds (62.5 percent) of the same group saw their tumors shrink significantly, with many experiencing substantial and long-lasting responses to the combined treatment.View evidenceHide evidence
As stated62.5 percent
Not checked
No source study was confirmed for this article. This claim remains unverified, rather than assessed as supported or unsupported.
Claim 3 of 6Not checkedThe findings came from the IOV-COM-202 international, multicenter phase II trial in advanced melanoma, presented at the 2026 European Society for Medical Oncology Congress.View evidenceHide evidence
Not checked
No source study was confirmed for this article. This claim remains unverified, rather than assessed as supported or unsupported.
Claim 4 of 6Not checkedResearchers said the study suggests introducing lifileucel earlier in treatment may improve outcomes, and that larger studies are needed to understand which patients benefit most.View evidenceHide evidence
Not checked
No source study was confirmed for this article. This claim remains unverified, rather than assessed as supported or unsupported.
Claim 5 of 6Not checkedThe article reports that patients experienced no additional side effects beyond those associated with the individual treatments.View evidenceHide evidence
Not checked
No source study was confirmed for this article. This claim remains unverified, rather than assessed as supported or unsupported.
Claim 6 of 6Not checkedThe article says the trial selected 27 patients with advanced melanoma, and 24 were included in the main analysis after a median follow-up of 26.9 months.View evidenceHide evidence
As stated27 patients; 24 in main analysis; 26.9 months
Not checked
No source study was confirmed for this article. This claim remains unverified, rather than assessed as supported or unsupported.
Method layer
Study not confirmed.
The search results are available for you to inspect. Without a confirmed source study, they cannot establish whether the story’s claims are supported or contradicted.
Search results
Candidate papers, not confirmed sources.
PubMed, Crossref · 15 candidate papers
Emerging immunotherapies in melanoma beyond immune checkpoint inhibitors: Vaccines, intralesional therapies, adoptive cell therapies, and T-cell engagers.
Cancer Treatment and Research Communications · 2026 · PubMed
TIL Therapy in Combination With Pembrolizumab Shows Promise in Patients With Immunotherapy-Naive, Advanced Melanoma
Default Digital Object Group · 2024 · Crossref
Novel tumor-infiltrating lymphocytes therapy in solid tumors: latest updates from 2025 ASCO annual meeting.
Experimental Hematology & Oncology · 2025 · PubMed
Lifileucel induces a durable response in heavily pretreated mucosal melanoma
Medicom Conference Report ESMO 2023 · 2023 · Crossref
Lifileucel (Amtagvi): A cellular therapy for melanoma.
The Medical Letter on Drugs and Therapeutics · 2024 · PubMed